NULLBODY
DEAD

Serial Number

77917378

Owner

KYOWA HAKKO KIRIN CO., LTD.

Attorney

Darren J. Jones

Filing Date

Jan 21, 2010

Add to watchlist:

No watchlists yet
View on USPTO

NULLBODY Trademark

Serial Number: 77917378 • Registration: 3983268

NULLBODY is a trademark filed by KYOWA HAKKO KIRIN CO., LTD. on January 21, 2010. The trademark is classified under Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

KYOWA HAKKO KIRIN CO., LTD. (58 trademarks)

1-6-1, OHTEMACHI, CHIYODA-KU
TOKYO , JP

Entity Type: 99

Trademark Details

Filing Date

January 21, 2010

Registration Date

June 28, 2011

Published for Opposition

February 15, 2011

Cancellation Date

February 2, 2018

Goods & Services

Contract manufacturing service in the field of antibodies, fragments of antibodies, and derivatives of antibodies; contract manufacturing service in the field of cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; contract manufacturing service in the field of transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; contract manufacturing service in the field of host cells; contract extracting, refining, synthesizing, manufacturing and preparing pharmaceuticals, agricultural chemicals, and chemicals; providing information in the field of manufacturing technology in the field of antibodies, fragments of antibodies, and derivatives of antibodies; technical consultation in the field of manufacturing technology in the field of antibodies, fragments of antibodies, and derivatives of antibodies; providing information in the field of manufacturing technology in the field of cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; technical consultation in the field of manufacturing technology in the field of cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; providing information in the field of manufacturing technology in the field of transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; technical consultation in the field of manufacturing technology in the field of transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; providing information in the field of manufacturing technology in the field of host cells; technical consultation in the field of manufacturing technology in the field of host cells; providing technical information in the field of extracting, refining, synthesizing, manufacturing and preparing pharmaceuticals, agricultural chemicals, and chemicals; technical consultation in the field of extracting, refining, synthesizing, manufacturing and preparing pharmaceuticals, agricultural chemicals, and chemicals

Host cells for medical or clinical use; cells that manufacture antibodies, fragments of antibodies or derivatives of antibodies for medical or clinical use; transfected cells that manufacture antibodies, fragments of antibodies or derivatives of antibodies for medical or clinical use; pharmaceuticals, namely, central nervous system depressants, preparations for ophthalmic use, anti-histaminics, cardiotonics, arrhythmia treating agents, diuretics, hypotensors, prophylactic for the treatment of asthma, antitussives and expectorants, stomachics and digestives, antacids, hormones, namely, pituitary hormones for the treatment of infertility, thyroid hormones for the treatment of hyperthyroidism, anabolic hormones for the treatment of aplastic anemia and osteoporosis, corticosteroids for treatment of hypopituitarism, congenital adrenal hyperplasia, rheumatoid arthritis, rheumatic fever, crohn's disease, and chronic active hepatitis, estrogen and progesterone used as combined oral contraceptives, urinary antiseptics, analgesics, anti-itching agents, cataplasms for the treatment of bruises, lumbago and stiff shoulder, pharmaceutical preparations used to treat hair disorders, vitamin preparations, food enriching agents for treating vitamin deficiencies, anti-coagulants, enzyme preparations for control of malabsorption and diarrhea, anti-cancer preparations, anti-sarcoma preparations, antibiotics and their preparations for the treatment of infectious diseases, antituberculotic agents, influenza vaccines, diphtheria vaccines, tetanus vaccines, gas gangrene vaccines, Japanese encephalitis vaccines, in vitro tetrodotoxines for medical use, antiprotozoals for the treatment of trichomoniasis and dermatophytosis, anthelmintics for the treatment of threadworm and toxoplasmaosis, naturally occurring drugs for treating peptic ulcers, charred drugs for treating peptic ulcers, moxa for treating peptic ulcers, veterinary drugs for the treatment of distemper in dogs, distomatosis in dogs, coccidian in chickens, and dysentery in pigs, germination controllers and plant rearing agents, namely, herbicides, fungicides, insecticides, bactericides and rodenticides for domestic and or agricultural use, antiseptics, drugs for arteriosclerosis, oncostatic drugs for the treatment of cancer, multi enzyme digestants for in vivo use, antifungal antibiotics for treating trichomoniasis and dermatophytosis, anti parkinsonism drugs, minor tranquilizers, and anti anxiety agents, medicinal preparations for the treatment of the central nervous system, the respiratory tract and the cardiovascular system, anti-bacterial preparations, monolithic preparations, medicinal preparations for the treatment of peptic ulcers, anti -inflammatory preparations, analgesic preparations, cephalosporin, cocarboxylase preparations, glutathione preparations, preparations for improving the metabolism and the peripheral circulation, plasma substitutes and extracorporeal circulation flow improvement preparations, diuretic and anti-hypertensive preparations, in vitro diagnostic reagents for medical use, in vitro extra corporeal diagnostic reagents for medical use, in vitro x-ray contrast agents for medical use, in vitro diagnostic media, pharmaceutical preparations for the treatment of insomnia and other sleep related diseases

Development of new products for others in the field of antibodies, fragments of antibodies, derivatives of antibodies, cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, and host cells; providing technical information in the field of development of new products in the field of antibodies, fragments of antibodies, derivatives of antibodies, cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, and host cells; technical consultation in the field of development of new products in the field of antibodies, fragments of antibodies, derivatives of antibodies, cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, and host cells

Filing History

CANCELLED SEC. 8 (6-YR)
Feb 2, 2018 C8..
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Jun 28, 2016 REM1
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Aug 11, 2011 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Aug 11, 2011 REAP
REGISTERED-PRINCIPAL REGISTER
Jun 28, 2011 R.PR
1(B) BASIS DELETED; PROCEED TO REGISTRATION
May 24, 2011 DP1B
CASE ASSIGNED TO INTENT TO USE PARALEGAL
May 24, 2011 AITU
NOTICE OF ALLOWANCE CANCELLED
May 20, 2011 IUCN
TEAS DELETE 1(B) BASIS RECEIVED
May 20, 2011 D1BR
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Apr 12, 2011 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 15, 2011 NPUB
PUBLISHED FOR OPPOSITION
Feb 15, 2011 PUBO
LAW OFFICE PUBLICATION REVIEW COMPLETED
Jan 7, 2011 PREV
ASSIGNED TO LIE
Jan 7, 2011 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 6, 2011 CNSA
EXAMINER'S AMENDMENT ENTERED
Jan 6, 2011 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jan 6, 2011 GNEN
EXAMINERS AMENDMENT E-MAILED
Jan 6, 2011 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jan 6, 2011 CNEA
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Jan 6, 2011 ZZZX
WITHDRAWN FROM PUB - OG REVIEW QUERY
Dec 20, 2010 PBCR
LAW OFFICE PUBLICATION REVIEW COMPLETED
Dec 8, 2010 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 6, 2010 CNSA
EXAMINER'S AMENDMENT ENTERED
Dec 1, 2010 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Dec 1, 2010 GNEN
EXAMINERS AMENDMENT E-MAILED
Dec 1, 2010 GNEA
EXAMINERS AMENDMENT -WRITTEN
Dec 1, 2010 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 10, 2010 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 10, 2010 CRFA
ASSIGNED TO LIE
Nov 10, 2010 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 22, 2010 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 26, 2010 GNRN
NON-FINAL ACTION E-MAILED
Apr 26, 2010 GNRT
NON-FINAL ACTION WRITTEN
Apr 26, 2010 CNRT
ASSIGNED TO EXAMINER
Apr 19, 2010 DOCK
NOTICE OF PSEUDO MARK MAILED
Jan 27, 2010 MPMK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 26, 2010 NWOS
NEW APPLICATION ENTERED
Jan 25, 2010 NWAP